// App-Quantinova.ai

DMT06 : Perceptions and Discussions on the Use of Disease-Modifying Therapies during Family Planning in Women with Multiple Sclerosis

Researchers

Presenter

  • Riley Bove

Principal Investigators

  • Noemi Pasquarelli

  • Marina Gafarova

  • Christine Eighteen

  • Natalie Joschko

  • Corey Mandel

  • Ruth Dobson

Medical Centers

  • Preventative Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

  • Roche Pharma AG, Grenzach-Wyhlen, Germany

  • Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco

  • Roche Moscow JSC, Moscow, Russian Federation

Locations

  • United States

  • Switzerland

  • Germany

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • glatiramer

  • Natalizumab

  • Ocrelizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved